Strategic Agenda for Filoviruses Research and Monitoring (AFIRM)
WHO-AFIRM Strategy Roadmap 2021-2031

Second Meeting, July 17, 2022
Anticipation

1. What data needs to be collected for prevention of future outbreaks? What kind of analysis models and co-operations do we need to acquire & analyze such data?

2. Would it be worthwhile to setup a web-based filovirus surveillance database?

3. Do we have the right diagnostic tools? If not, what tools need to be implemented?

4. What tools do we have in place to prevent relapse and initiation of outbreaks via transmission from survivors?

5. What is the role of domestic animal and wildlife surveillance for outbreak prevention? What is the best strategy?
Reinforcement

1. What data is missing to allow immunobridging of filovirus vaccines? What is the fastest strategy to acquire such data?

2. Is it possible to develop multivalent virus vaccines?

3. How can we better accelerate the development of vaccines against Marburg and Sudan viruses?

4. Are there vaccines based on other platforms in the pipeline that can reinforce the response after vaccination of the current approved vaccines?

5. Is there a need to boost immunity in survivors?

6. Input on WHO protocol for filovirus vaccine trials.
Cure

1. How can we better share the knowledge gained in previous outbreaks to treat filovirus patients? Is this knowledge translatable to all filovirus diseases?

2. Which interventions improve outcome, in particular preventing multiorgan failure?

3. What post-exposure therapies or combinations thereof are preferred? Do they have prophylactic potential as well?

4. How can we improve collaboration in endemic countries?